Initiate a controlled, randomized, Phase IIb study in sepsis
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 1 Mar 2021
- Due
- 31 Mar 2021
- Delivered
- Q1 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“plans to initiate a controlled, randomized, Phase IIb study in sepsis during the first quarter of 2021”
What we found
Evidence strength A What the grades mean
The 20-F filed April 30, 2021 says the company initiated a randomized, controlled Phase IIb sepsis trial in Q1 2021, meeting the deadline.
-
A Enlivex Therapeutics Ltd. 20-F filed 2021-04-30
“the Company initiated in the first quarter of 2021 a randomized, controlled Phase IIb clinical trial, which is expected to recruit up to 160 patients” ✓ confirmed on the page
-
A Enlivex Therapeutics Ltd. 20-F filed 2021-04-30
“the Company initiated in the first quarter of 2021 a randomized, controlled Phase IIb clinical trial” ✓ confirmed on the page
-
A Enlivex Therapeutics Ltd. 6-K filed 2021-05-18
“Enlivex is currently recruiting patients to its Phase IIb trial of AllocetraTM for the treatment of organ dysfunctions associated with sepsis.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase IIb sepsis study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Enlivex Therapeutics Ltd.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ENLV-024868 · Corrections policy